Biologics CDMO Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The biologics cdmo market size has grown rapidly in recent years. It will grow from $21.3 billion in 2024 to $24.37 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to rise in biologics development, cost efficiency and flexibility, focus on core competencies, regulatory compliance and quality assurance, globalization of pharmaceutical supply chains.

The biologics cdmo market size is expected to see rapid growth in the next few years. It will grow to $42.33 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to increasing demand for biologic therapies, emergence of biosimilars and biobetters, investments in biomanufacturing infrastructure, shift towards outsourcing complex processes, focus on supply chain resilience and risk mitigation, regulatory harmonization, and expedited approvals. Major trends in the forecast period include expansion of capabilities to offer end-to-end solutions, adoption of single-use technologies, integration of continuous manufacturing processes, emergence of specialized CDMOs.

The surge in demand for cell and genetic therapy is expected to propel the growth of the biologic CDMO market going forward. Cell and gene therapy are innovative medical approaches that utilize living cells or genetic material to address underlying disease causes at the cellular or genetic level, providing potential treatments for conditions that are difficult to manage or incurable with traditional pharmaceuticals. The demand for cell and gene therapy is rising due to their potential to offer innovative treatments for diseases by addressing underlying genetic or cellular causes. Biologic CDMOs provide expertise in handling living cells, viral vectors, and genetic material, facilitating safe and efficient production of cell and gene therapies while assisting biopharmaceutical companies in navigating regulatory requirements and technical challenges, thereby facilitating translation from research to clinical application. For instance, in January 2023, according to The American Society of Gene & Cell Therapy (ASGCT), a US-based primary professional membership organization, the gene, cell, and RNA therapy pipeline saw 7% growth in 2022, reaching a total of 3,726 therapies in development. Of these, 55% are gene therapies, while 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Therefore, the surge in demand for cell and genetic therapy is driving the growth of the biologic CDMO market.

Major companies operating in the biologics CDMO market are developing technologically advanced solutions, such as new cell lines, to enhance biopharmaceutical development and manufacturing efficiency and capabilities. The technology produces therapeutic antibodies with enhanced potency, addressing immunotherapy research and development challenges. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company that specializes in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines, designed to produce antibodies that are 100% free of fucose, a sugar molecule and demonstrate increased potency without compromising on other performance attributes. It helps overcome immunotherapy research and development challenges related to the need for antibody therapeutics to increase potency. It is a stable, scalable, and productive cell line that provides a solution for therapeutic development from discovery-stage research through commercial manufacturing.

In May 2022, Bora Pharmaceuticals Co. Ltd., a Taiwan-based organization that specializes in manufacturing and selling pharmaceutical products, acquired the CDMO assets of Eden Biologics Inc. for $100 million. The aim of the acquisition is to expand its presence in the global CDMO market, particularly focusing on biologics, macromolecules, and cell and gene therapy markets. Eden Biologics Inc. is a Taiwan-based biotechnology company specializing in the contract development and manufacturing of innovative biologics for therapeutic applications.

Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics CDMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biologics CDMO market consist of revenues earned by entities by providing services such as process development, analytical development, cell line development, supply chain management, and fill-finish services. The biologics CDMO market also includes sales of monoclonal antibodies, recombinant proteins, antisense and molecular therapy, and vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

A biologics contract development and manufacturing organization (CDMO) is a service provider that supports pharmaceutical companies in the development and production of biologic drugs, which include vaccines, blood and blood components, allergens, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins.

The main cell types in biologics CDMO are mammalian and non-mammalian. Mammalian refers to cell lines derived from mammals, commonly used in the production of biologics and cell-based therapies due to their ability to produce complex proteins and maintain post-translational modifications. The various products types include biologics and biosimilars.

The main cell types in biologics CDMO are mammalian and non-mammalian. Mammalian refers to cell lines derived from mammals, commonly used in the production of biologics and cell-based therapies due to their ability to produce complex proteins and maintain post-translational modifications. The various products types include biologics and biosimilars.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.